Abstract:e23123 Background: Pleural carcinosis caused by tumors of the chest (e.g., lung and breast cancer) or elsewhere in the body (e.g., ovarian carcinoma) that metastasize to the visceral and/or parietal pleura. Recurrent malignant pleural effusion due to pleural carcinosis is one of the most common findings in oncology. The aim of the study was to identify a miRNA signature associated with clinicians’ prescription of patients with MPE. Methods: We used qRT-PCR assay to evaluate a wide range miRNAs (1920 miRNAs) signature measured from pleural effusion between patients with cancer and healthy controls. From the data of our previous studies we selected a panel of 96 miRNAs related to malignant pleural effusion. Data were compared by three classification methods software for statistics and modeling. We used a first set of 77 pleural effusion samples as training group, including 27 patients affected by Lung Adenocarcinomas (LAC), 9 with other lung cancer, 17 with other tumors and 24 inflammatory patients as negative controls. Moreover, we used more 64 pleural effusion samples for double-blind predictive study. Data analysis was performed using a machine learning approach of a Support Vector Machine classifier with a Student's t-test feature selection procedure. Results: We identified a panel of ten miRNAs with optimum classification performance. The combination of these 10-miRNAs alone could discriminate MPE cases from negative controls with an AUC of 0.969 (accuracy = 93.5%; specificity = 91.7%). The selected panel of another 10-miRNAs could separate lung cancer cases from negative controls with an AUC of 0.973 (accuracy = 94.8%; specificity = 95.8%), and a small panel of 4-miRNAs could good discriminate LAC cases from negative controls with an AUC of 0.946 (accuracy 88.9%; specificity = 100%). The accuracy rate of the double-blind predictive sensitivity value was 90.9% and specificity value was 95.8% for MPE patients with lung cancer of miRNA signature. Conclusions: Our miRNAs profile may serve as a new biomarker for MPE diagnosis. Otherwise, we identified a 10-miRNAs signature for MPE patients with lung cancer and a 4-miRNAs for MPE patients with lung adenocarcinoma.

Diagnostic and Predictive Role of Cell-Free Midkine in Malignant Pleural Effusions

MDK Protein Overexpression Correlates with the Malignant Status and Prognosis of Non-small Cell Lung Cancer

Expression of Midkine in Ameloblastomas and Its Correlation with Clinicopathologic Parameters.

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

Cell-free Mir-24 and Mir-30D, Potential Diagnostic Biomarkers in Malignant Effusions.

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

High Expression of Midkine (MK) Indicates Poor Prognosis in Childhood Acute Lymphoblastic Leukemia.

Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions

Detection of Cell-Free BIRC5 Mrna in Effusions and Its Potential Diagnostic Value for Differentiating Malignant and Benign Effusions.

Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer

Exosomal Let-7D-3p and Mir-30D-5p As Diagnostic Biomarkers for Non-Invasive Screening of Cervical Cancer and Its Precursors

MicroRNAs – novel biomarkers for malignant pleural effusions

Methylated DNA and Microrna in Body Fluids As Biomarkers for Cancer Detection

Prognostic and diagnostic effects of high serum midkine levels in patients with hepatocellular carcinoma

Data from Evaluation of Midkine As a Diagnostic Serum Biomarker in Hepatocellular Carcinoma

Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer

Circulating MicroRNA Panel As a Diagnostic Marker for Hepatocellular Carcinoma

Midkine (MDK) in Hepatocellular Carcinoma: More than a Biomarker

A Multicancer Malignant Pleural Effusion Diagnostic Test Using Hexokinase 2 and Single-Cell Sequencing.

A Detection Panel of Novel Methylated DNA Markers for Malignant Pleural Effusion

Midkine Is a Potential Urinary Biomarker for Non-Invasive Detection of Bladder Cancer with Microscopic Hematuria